Open Access
- Published by Korean Cancer Association
- Vol. 72 (4) , 440-448
Abstract
Treatment of neurological disorders with intravenous immunoglobulin (IVIg) is an increasing feature of our practice for an expanding range of indications. For some there is evidence of benefit from randomised controlled trials, whereas for others evidence is anecdotal. The relative rarity of some of the disorders means that good randomised control trials will be difficult to deliver. Meanwhile, the treatment is costly and pressure to “do something” in often distressing disorders considerable. This review follows a 1 day meeting of the authors in November 2000 and examines current evidence for the use of IVIg in neurological conditions and comments on mechanisms of action, delivery, safety and tolerability, and health economic issues. Evidence of efficacy has been classified into levels for healthcare interventions (tables 1 and 2).Keywords
This publication has 97 references indexed in Scilit:
- Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin GThe Journal of Pediatrics, 1997
- Immune modulation of paraneoplastic neurologic disordersClinical Neurology and Neurosurgery, 1995
- Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibodyClinical Neurology and Neurosurgery, 1995
- Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibodyClinical Neurology and Neurosurgery, 1995
- Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases.Archives of Disease in Childhood, 1995
- Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki diseaseClinical and Experimental Immunology, 1994
- IgG Induction of IL‐1 Receptor Antagonist Production by Human MonocytesImmunological Reviews, 1994
- Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulinThe Journal of Pediatrics, 1990
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinNew England Journal of Medicine, 1986
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR MYASTHENIA GRAVISThe Lancet, 1984